Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 489 Results

Page 41 of 49« First «...10 20 30...39 404142 43...»Last »

March 6, 2015

DBV Technologies to Present at Upcoming Investor Conferences

February 24, 2015

Viaskin^® Data Presented at AAAAI Meeting Show Safety and Efficacy in the Treatment of Food Allergies

February 13, 2015

DBV Technologies Welcomes Dr. J-P Moreau to its Scientific Advisory Board

February 3, 2015

DBV Technologies to Present at the 2015 Leerink Partners Global Healthcare Conference in New-York (USA)

February 3, 2015

Largest Presence Ever of DBV Technologies at 2015 Allergy Meeting

January 29, 2015

DBV Technologies Announces Topline Financial Results for Full Year 2014

January 14, 2015

Half year update on the DBV Technologies liquidity agreement

January 12, 2015

DBV Technologies Announces Publication in the Journal of Allergy and Clinical Immunology of Data Demonstrating that Epicutaneous Immunotherapy may Influence the Natural History of Allergy

January 8, 2015

DBV Technologies Provides Organizational Update

November 20, 2014

DBV Technologies Initiates Phase I/II Clinical Trial with Viaskin Milk for the Treatment of Children with Cow’s Milk Allergy

Page 41 of 49« First «...10 20 30...39 404142 43...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Your California Privacy Rights

Scroll to Top